12 min
Fast Five: Dexcom gets first OTC CGM nod from FDA, ResMed launches new mask Fast Five Medtech News Podcast
-
- News
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, March 7, 2024.
Check out the show notes at MassDevice.com/podcast.
Abbott reported some positive real-world data on the use of its CGM with GLP-1s. Fast Five hosts Chris Newmarker and Sean Whooley take a look at the emergence of GLP-1s in medtech and the potential to bolster CGM technologies.
Gradient began a U.S. trial for its pulmonary denervation technology. With renal denervation garnering so much attention recently, the hosts examine another denervation technology for treating hypertension.
Orthofix posted Street-beating fourth-quarter results. With tons of changes at Orthofix over the past year, analysts seem more positive about these latest results. The Fast Five hosts look at some of the key figures from the quarter and how Orthofix can right the ship.
ResMed launched a new face mask for sleep apnea patients. With recalls all over the place in the sleep apnea market, including at ResMed, this could prove a significant launch. Newmarker and Whooley break down some of the history of the market and look at the standout features of this mask.
The FDA cleared the first over-the-counter CGM, with Dexcom’s Stelo getting the nod. Listen to hear all about this new technology and how it could provide a boost to many within the diabetes community.
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, March 7, 2024.
Check out the show notes at MassDevice.com/podcast.
Abbott reported some positive real-world data on the use of its CGM with GLP-1s. Fast Five hosts Chris Newmarker and Sean Whooley take a look at the emergence of GLP-1s in medtech and the potential to bolster CGM technologies.
Gradient began a U.S. trial for its pulmonary denervation technology. With renal denervation garnering so much attention recently, the hosts examine another denervation technology for treating hypertension.
Orthofix posted Street-beating fourth-quarter results. With tons of changes at Orthofix over the past year, analysts seem more positive about these latest results. The Fast Five hosts look at some of the key figures from the quarter and how Orthofix can right the ship.
ResMed launched a new face mask for sleep apnea patients. With recalls all over the place in the sleep apnea market, including at ResMed, this could prove a significant launch. Newmarker and Whooley break down some of the history of the market and look at the standout features of this mask.
The FDA cleared the first over-the-counter CGM, with Dexcom’s Stelo getting the nod. Listen to hear all about this new technology and how it could provide a boost to many within the diabetes community.
12 min